Letter to the Editor
Allergic asthma and omalizumab – The experience at the Centro Hospitalar Cova da Beira
Asma alérgica e omalizumab - A experiência no Centro Hospitalar da Cova da Beira
M.S. Saldanha Mendes
, M.J. Valente, I. Vicente, E. Magalhães, S. Valente
Corresponding author
Centro Hospitalar da Cova da Beira, CPE, Covilhã, Portugal
Read
989
Timeswas read the article
515
Total PDF
474
Total HTML
Share statistics
array:24 [ "pii" => "S2173511513000468" "issn" => "21735115" "doi" => "10.1016/j.rppnen.2013.03.004" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "aid" => "152" "copyright" => "Sociedade Portuguesa de Pneumologia" "copyrightAnyo" => "2012" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2013;19:186-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3859 "formatos" => array:3 [ "EPUB" => 248 "HTML" => 2513 "PDF" => 1098 ] ] "Traduccion" => array:1 [ "pt" => array:20 [ "pii" => "S0873215913000378" "issn" => "08732159" "doi" => "10.1016/j.rppneu.2013.03.003" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "aid" => "152" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2013;19:186-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6107 "formatos" => array:3 [ "EPUB" => 249 "HTML" => 4768 "PDF" => 1090 ] ] "pt" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta ao Editor</span>" "titulo" => "Asma alérgica e omalizumab – A experiência no Centro Hospitalar da Cova da Beira" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "186" "paginaFinal" => "187" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Allergic asthma and omalizumab - The experience at the Centro Hospitalar da Cova da Beira" ] ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Simões Saldanha Mendes, M.J. Valente, I. Vicente, E. Magalhães, S. Valente" "autores" => array:5 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Simões Saldanha Mendes" ] 1 => array:2 [ "nombre" => "M.J." "apellidos" => "Valente" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Vicente" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Magalhães" ] 4 => array:2 [ "nombre" => "S." "apellidos" => "Valente" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173511513000468" "doi" => "10.1016/j.rppnen.2013.03.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511513000468?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215913000378?idApp=UINPBA00004E" "url" => "/08732159/0000001900000004/v2_201509041415/S0873215913000378/v2_201509041415/pt/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2173511513000626" "issn" => "21735115" "doi" => "10.1016/j.rppnen.2013.07.005" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "aid" => "163" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "dis" "cita" => "Rev Port Pneumol. 2013;19:184-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3230 "formatos" => array:3 [ "EPUB" => 281 "HTML" => 2122 "PDF" => 827 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comment</span>" "titulo" => "Mechanically Assisted Invasive Ventilation for ALS patients: Is it the Ultimate Strategy To Improve Survival?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "184" "paginaFinal" => "185" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "A Ventilação Mecânica Invasiva na Esclerose Lateral Amiotrófica: a derradeira estratégia?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Anabela C. Pinto" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Anabela C." "apellidos" => "Pinto" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511513000626?idApp=UINPBA00004E" "url" => "/21735115/0000001900000004/v1_201308011255/S2173511513000626/v1_201308011255/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Allergic asthma and omalizumab – The experience at the Centro Hospitalar Cova da Beira" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "186" "paginaFinal" => "187" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M.S. Saldanha Mendes, M.J. Valente, I. Vicente, E. Magalhães, S. Valente" "autores" => array:5 [ 0 => array:4 [ "nombre" => "M.S." "apellidos" => "Saldanha Mendes" "email" => array:1 [ 0 => "marianacarocha@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "M.J." "apellidos" => "Valente" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Vicente" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Magalhães" ] 4 => array:2 [ "nombre" => "S." "apellidos" => "Valente" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Centro Hospitalar da Cova da Beira, CPE, Covilhã, Portugal" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Asma alérgica e omalizumab - A experiência no Centro Hospitalar da Cova da Beira" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Since 2003, when Omalizumab was first approved by the Food and Drug Administration, severe allergic asthma treatment has never been the same. This humanized monoclonal antibody selectively binds to IgE, preventing its interaction with the Fc¿RI receptor (IgE high-affinity receptor) on the surface of mast cells and basophils. In this way, release of inflammatory mediators is prevented.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> It is indicated for the treatment of severe uncontrolled allergic asthma, unresponsive to high-dose inhaled corticosteroids.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We wanted to share our rewarding experience with Omalizumab in Centro Hospitalar da Cova da Beira (CHCB), so we carried out a retrospective evaluation of the effects of Omalizumab in terms of clinical control of asthma, pulmonary function, number of visits to health facilities, and dependency on high-dose inhaled corticosteroids and long-acting beta-agonists. From a total of 15 individuals eligible for Omalizumab therapy, we found a statistically significant increase in median FEV1 (from 62.3% before Omalizumab, to 77.4% after 4–6 months and 80.75% after 10–12 months of treatment), in the clinical control of asthma according to the Asthma Control Test (40% partially controlled and 47% totally controlled patients after 4–6 months, and 40% partially controlled and 60% totally controlled patients after 10–12 months of treatment), a statistically significant decrease in the number of hospital admissions (0.56/year to 0.0/year), and in emergency admissions related to asthma exacerbations (1.01–0.14 episodes/year). There were no changes in the inhaled corticosteroids and long-acting beta-agonist doses.</p><p id="par0015" class="elsevierStylePara elsevierViewall">We were expecting the benefits recorded at the CHCB, considering the results of numerous previous studies, which have consistently showed a significant connection between the administration of Omalizumab and clinical improvement, a decrease in the need for asthma medication, as well as in the number of hospitalizations, unscheduled visits and emergency episodes.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Furthermore, several studies have demonstrated that add-on Omalizumab therapy is cost-effective in patients with severe persistent allergic asthma.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In conclusion, we believe that the costs of the Omalizumab therapy should not act as a constraint on prescribing it, when indicated. Decisions should be taken with a medium/long term perspective, bearing in mind that those patients for whom Omalizumab is indicated and not prescribed will eventually need extra health care with avoidable expense.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Ethical disclosures</span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Protection of human and animal subjects</span><p id="par0025" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were performed on humans or animals for this study.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Confidentiality of data</span><p id="par0030" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Right to privacy and informed consent</span><p id="par0035" class="elsevierStylePara elsevierViewall">The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.</p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conflicts of interest</span><p id="par0040" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0005" "titulo" => "Ethical disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0015" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0020" "titulo" => "Right to privacy and informed consent" ] ] ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Conflicts of interest" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Simões Saldanha Mendes M, et al. Asma alérgica e omalizumab - A experiência no Centro Hospitalar da Cova da Beira. Rev Port Pneumol. 2013. <span class="elsevierStyleInterRef" id="intr0005" href="http://dx.doi.org/10.1016/j.rppneu.2013.03.003">http://dx.doi.org/10.1016/j.rppneu.2013.03.003</span>.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab in the management of patients with allergic (IgE-mediated) asthma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "T. Sandström" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Asthma Allergy" "fecha" => "2009" "volumen" => "2" "paginaInicial" => "49" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21437144" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109712001908" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M.H. Lafeuille" 1 => "J. Dean" 2 => "J. Zhang" 3 => "M.S. Duh" 4 => "B. Gorsh" 5 => "P. Lefebvre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.anai.2012.04.015" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2012" "volumen" => "109" "paginaInicial" => "59" "paginaFinal" => "64" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22727159" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R.W. Costello" 1 => "D.A. Long" 2 => "S. Gaine" 3 => "T. McDonnell" 4 => "J.J. Gilmartin" 5 => "S.J. Lane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11845-011-0716-2" "Revista" => array:6 [ "tituloSerie" => "Ir J Med Sci" "fecha" => "2011" "volumen" => "180" "paginaInicial" => "637" "paginaFinal" => "641" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21557095" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R.W. Dal Negro" 1 => "L. Pradelli" 2 => "S. Tognella" 3 => "C. Micheletto" 4 => "S. Iannazzo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Eur Ann Allergy Clin Immunol" "fecha" => "2011" "volumen" => "43" "paginaInicial" => "45" "paginaFinal" => "53" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21608372" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673611616723" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735115/0000001900000004/v1_201308011255/S2173511513000468/v1_201308011255/en/main.assets" "Apartado" => array:4 [ "identificador" => "9715" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letter to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735115/0000001900000004/v1_201308011255/S2173511513000468/v1_201308011255/en/main.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511513000468?idApp=UINPBA00004E" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 1 | 8 |
| 2024 October | 23 | 31 | 54 |
| 2024 September | 34 | 19 | 53 |
| 2024 August | 51 | 35 | 86 |
| 2024 July | 24 | 40 | 64 |
| 2024 June | 25 | 41 | 66 |
| 2024 May | 34 | 42 | 76 |
| 2024 April | 23 | 25 | 48 |
| 2024 March | 26 | 22 | 48 |
| 2024 February | 28 | 26 | 54 |
| 2024 January | 17 | 24 | 41 |
| 2023 December | 15 | 24 | 39 |
| 2023 November | 21 | 31 | 52 |
| 2023 October | 18 | 27 | 45 |
| 2023 September | 18 | 29 | 47 |
| 2023 August | 17 | 26 | 43 |
| 2023 July | 21 | 22 | 43 |
| 2023 June | 24 | 10 | 34 |
| 2023 May | 34 | 28 | 62 |
| 2023 April | 14 | 12 | 26 |
Show all
